Fatty Liver and Lipotropic Factors

Fatty Liver & Pathogenesis - Greasy Guts Genesis

• Hepatic Steatosis: Fat accumulation in >5% of hepatocytes.
  • NAFLD: Non-Alcoholic Fatty Liver Disease; common with metabolic syndrome.
  • AFLD: Alcoholic Fatty Liver Disease; due to chronic alcohol use.
• Pathogenesis - Key Mechanisms: 📌 Mnemonic: Too much IN, too much MADE, too little BURNED, too little SENT OUT.
  • ↑ Increased Free Fatty Acid (FFA) influx from adipose tissue/diet.
  • ↑ Increased De Novo Lipogenesis (DNL) (hepatic fat synthesis).
  • ↓ Decreased FFA β-oxidation (fat breakdown).
  • ↓ Decreased VLDL (Very Low-Density Lipoprotein) export; impaired by defects in ApoB-100 synthesis or MTP (Microsomal Triglyceride Transfer Protein) function.
• Key Molecular Regulators:
  • Insulin Resistance: Central driver, esp. in NAFLD.
  • SREBP-1c (Sterol Regulatory Element-Binding Protein-1c): Activated by insulin; ↑ DNL.
  • ChREBP (Carbohydrate Responsive Element-Binding Protein): Activated by carbohydrates; ↑ DNL.

⭐ Insulin resistance is a central pathogenic factor in NAFLD, linking it to metabolic syndrome.

Lipotropic Factors - The De-Greasing Crew

• Definition: Agents that promote fat export from the liver, preventing/correcting hepatic steatosis.
• Key Lipotropic Factors: 📌 Mnemonic: Can My Baby Ingest Folate/B12?
  • Choline
  • Methionine
  • Betaine
  • Inositol
  • Folic acid & Vitamin B12 (co-factors in methyl transfer)
• Mechanisms of Action:
  • Choline: Synthesizes phosphatidylcholine for VLDL particles, essential for exporting triglycerides from hepatocytes.

    ⭐ Choline is crucial for VLDL assembly and export; its deficiency leads to triglyceride accumulation in the liver.

  • Methionine: Provides S-adenosylmethionine (SAMe), a key methyl donor.
    • Choline synthesis precursor (transmethylation).
    • Glutathione synthesis (antioxidant, protects liver).
  • Betaine: Methyl donor; converts homocysteine to methionine, spares choline, supports SAMe.
  • Inositol: Phospholipid (phosphatidylinositol) component; involved in cell membranes, signaling, lipid metabolism.

Clinical & Management - Spot & Stop Steatosis

• Clinical Features & Progression:
  • Often asymptomatic. May include fatigue, RUQ discomfort, hepatomegaly.
  • Spectrum: Simple steatosis (NAFL) → NASH (inflammation, hepatocyte injury) → Fibrosis → Cirrhosis (potential HCC).
• Diagnostic Workup:
  • Labs:
    • LFTs: ↑ALT > AST (NAFLD); AST:ALT > 2 (AFLD).
    • Dyslipidemia (↑TG, ↓HDL).
  • Imaging:
    • USG: Hyperechoic liver (initial, screening).
    • FibroScan (stiffness for fibrosis), MRI-PDFF (quantifies fat).
  • Liver Biopsy: Gold standard for NASH diagnosis, fibrosis staging; not routine for all.
• Management Approach:
  • NAFLD:
    • Lifestyle modification (cornerstone): Weight loss (7-10%), Mediterranean diet, regular exercise (150 min/wk moderate).
  • AFLD: Complete alcohol cessation.
  • Lipotropic Factors: (e.g., Choline, Methionine, Vitamin E for biopsy-proven NASH in non-diabetics). Role supplemental, evidence varies.

⭐ In NAFLD, ALT is typically higher than AST. In alcoholic liver disease (AFLD), an AST:ALT ratio >2 is characteristic, often with elevated GGT.

High‑Yield Points - ⚡ Biggest Takeaways

• Fatty liver (hepatic steatosis) is characterized by excess triglyceride accumulation in hepatocytes.
• Major causes include chronic alcohol abuse, obesity (NAFLD/NASH), diabetes mellitus, and protein-energy malnutrition.
• Pathophysiology involves an imbalance between hepatic triglyceride synthesis and its secretion as VLDL.
• Lipotropic factors such as choline, methionine, betaine, and inositol prevent or correct fatty liver.
• These factors promote VLDL assembly/secretion (e.g., choline for phosphatidylcholine) or act as methyl donors.
• Deficiency of these factors results in impaired VLDL export and hepatic fat accumulation.